Research Focus

Neurology

Area of Research

Acute cerebrovascular diseases and their management with focus on endovascular treatment and intravenous thrombolysis. Secondary Prevention of Stroke: randomized clinical trials, dyslipidemia, ideal time to start anticoagulant therapy after a stroke. Cohort studies on novel blood markers. Copeptin as first blood marker for prognosis after stroke and TIA. Prehospital stroke care networks to reduce delays. Safety and effectiveness of fast-track vs. open-end hospitalizations.

• AtheroGEnic LipoprotEinS in Ischemic Stroke - The AGELESS Study (Sponsor: Schweizerischer Nationalfond)
• Serum Neurofilaments Light Chain in Acute Ischemic Stroke and Transient Ischemic Attack (cohort study).
• Endovascular Treatment versus Best Medical Treatment for Ischemic Stroke with Large Vessel Occlusion in the 6–24 Hour Window among Non- DAWN-Non-DEFUSE Patients (Study based on the Swiss Stroke Registry)
• Apolipoprotein (B) and Lipoprotein(a) in Patients with Acute Ischemic Stroke 

National Collaborations

• Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study (NCT02274727)
• Midregion Proatrial Natriuretic Peptide to Guide Secondary Stroke Prevention (ongoing, steering committee member, NCT03961334)
• Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN, NCT03148457)
• Swiss Atrial Fibrillation Cohort (SWISS AF)

International Collaborations

• Tenecteplase in Wake-Up Stroke Trial (ongoing, steering committee member, NCT03181360)
• PACIFIC-STROKE (ongoing, steering committee member, NCT04304508)

• AtheroGEnic LipoprotEinS in Ischemic Stroke - The AGELESS Study (Sponsor: Schweizerischer Nationalfond)
• Endovascular Treatment versus Best Medical Treatment for Ischemic Stroke with Large Vessel Occlusion in the 6–24 Hour Window among Non- DAWN-Non-DEFUSE Patients (Study based on the Swiss Stroke Registry)
• Apolipoprotein (B) and Lipoprotein(a) in Patients with Acute Ischemic Stroke